A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation) caused by herpes simplex virus (HSV) does not ...

Herpes simplex virus (HSV) encephalitis, caused by HSV types 1 and 2, is the most common sporadic viral encephalitis worldwide, with an annual incidence of around 2·2–4·6 per million people.1 Before ...

A major UK clinical trial has shown that adding the corticosteroid dexamethasone to standard antiviral treatment for encephalitis (brain inflammation), caused by herpes simplex virus (HSV) does not ...

Please provide your email address to receive an email when new articles are posted on . Herpes simplex encephalitis (HSE) is likely the most serious herpes infection patients can face. Treatment ...

BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage ...

Defects in a single protein involved in cell death may impair the immune system's ability to combat a herpes viral infection in the central nervous system, scientists have found in new research that ...

This case illustrates many of the diagnostic challenges that may be encountered in patients presenting with herpes simplex infection of the brain. The patient had presented with transient focal ...

The herpes simplex virus-1 can sometimes cause a dangerous brain infection. Combining an anti-inflammatory and an antiviral could help in these cases, report scientists with the Rajewsky and ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. Germany’s ...

About 3.7 billion people carry the herpes simplex virus-1 in our nerve cells where it lies quiescent until triggered by stress or injury. When activated, its symptoms are usually mild, limited to cold ...

The MarketWatch News Department was not involved in the creation of this content. BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical ...